Menu Breaking news sponsored byAbbott Laboratories (NYSE:ABT) is ranked as a Buy using the stock evaluator from Portfolio Grader, which incorporates Louis Navellier's investing system. This represents no change from the previous week and is the same ranking ABT has had from Portfolio Grader for 2 months.As one of the 785 companies in the GICS Health Care sector ABT is a member of the 164 company Health Care Equipment & Supplies GICS industry group within this sector. ABT has a market value of $96.6 billion which is in the top decile in its industry group Portfolio Grader's current ranking for ABT puts it 31 among the 164 companies in this industry group, putting in the top quartile.The Health Care sector is ranked number 10 among the 12 sectors in the Portfolio Grader universe putting it in the bottom quartile of all the GICS sectors. The Health Care Equipment & Supplies industry group is ranked 40 among the 69 industry groups within the GICS sectors, placing it below-average in terms of the Navellier scoring system.ABT has received above-average scores in 2 of the 8 fundamental areas analyzed by Portfolio Grader and average or below-average grades in 6 of the areas used in the ranking of company stocks.ABT's operational scores provide mixed results with a ranking for sales growth that is well above the industry average but rankings for operating margin and earnings growth are below average. Scores for visibility of earnings are mixed, with rankings for earnings surprises and earnings revisions that are worse than average, while the score for earnings momentum is much better than average. ABT's grades for return on equity and cash flow are worse than its industry group average. Abbott Laboratories' fundamental scores give ABT a place in the top quartile of the industry group. Portfolio Grader uses the Navellier Proprietary Quantitative Score to view ABT's shares from the aspect of risk/reward. This unique scoring system weighs the relative value of the company's shares based on the current price of the shares relative to its peers, the market and risk associated with its industry and sector groups. Based on this risk/reward calculation, ABT currently scores well above-average in its industry group compared to its peers.Louis Navellier's proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results, with A being 'strong buy' and F being 'strong sell'.  Explore the tool here.Commentary provided by UpTick Data Technologies.Article printed from InvestorPlace Media, https://investorplace.com/2017/11/abbott-laboratories-abt-high-level-sales-growth-make-it-a-buy/.©2017 InvestorPlace Media, LLC

								About Us							
							  ·  													
								Press Center							
							  ·  													
								Resources							
							  ·  													
								Advisory Services							
							  ·  													
								Free Newsletters							
							  ·  													
								Free Reports							
							  ·  													
								Contact Us							
							  ·  													
								Advertise With Us							
							  ·  													
								Employment							
							  ·  													
								Privacy							
							  ·  													
								Terms and Conditions							
							  ·  													
								Disclosures and Disclaimers							
							  ·  													
								Media Sites							


								RSS							
							  ·  													
								Sitemap							

More On InvestorPlace:
Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.Copyright © 2017 InvestorPlace Media, LLC. All rights reserved. 9201 Corporate Blvd, Rockville, MD 20850.